LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
- Company: Shanghai Sun-shine bio-technology Co., Ltd
- Country: China (Mainland)
- Market: European Union,Americas
- Founded Year: 2009
- Address: 武汉东湖高新区长城科技园光谷精工D栋402室
- Contact: Rosie Liu